IIM
UTHR icon

Illumine Investment Management’s United Therapeutics UTHR Stock Holding History

Illumine Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,735
Closed -$4.36M – 5
2026
Q1 		$4.59M Sell
7,735
-553
-7% -$275K 3.53% 1
2025
Q4 		$4.04M Sell
8,288
-227
-3% -$106K 2.94% 6
2025
Q3 		$3.57M Sell
8,515
-141
-2% -$47.4K 2.54% 11
2025
Q2 		$2.49M Buy
8,656
+52
+0.6% +$15.5K 1.98% 18
2025
Q1 		$2.65M Buy
8,604
+58
+0.7% +$19.9K 2.17% 15
2024
Q4 		$3.02M Buy
+8,546
New +$3.14M 2.48% 10

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Illumine Investment Management's UTHR Position: Q2 2026 in Review

Illumine Investment Management sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 7,735 shares — an estimated $4.36M sold.

Illumine Investment Management first reported a position in UTHR in Q4 2024 and held it in 6 quarters. The position peaked at $4.59M in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Illumine Investment Management reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Illumine Investment Management sold 7,735 United Therapeutics shares in Q2 2026, an estimated $4.36M.
  • Illumine Investment Management first reported a position in United Therapeutics in Q4 2024 and held it in 6 quarters.
  • Illumine Investment Management's United Therapeutics position peaked at $4.59M in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Illumine Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.